HC Wainwright & Co. Maintains Buy on Summit Therapeutics, Lowers Price Target to $44
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Summit Therapeutics but lowered the price target from $45 to $44.

October 31, 2024 | 11:40 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained a Buy rating on Summit Therapeutics but lowered the price target from $45 to $44.
The analyst's decision to maintain a Buy rating suggests continued confidence in the company's prospects, which is positive. However, the slight reduction in the price target indicates a minor adjustment in expectations, which could be seen as a neutral factor in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100